On Guidelines for Comparative Effectiveness Research Using Nonrandomized Studies in Secondary Data Sources
ISPOR Health Policy Council Proposed Good Research Practices for Comparative Effectiveness Research: Benefit or Harm?
Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part I
Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II
Good Research Practices for Comparative Effectiveness Research: Analytic Methods to Improve Causal Inference from Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report—Part III
Establishing Optimal Requirements for Content Validity: A Work in Progress
Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification: The ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report
The Imperative to Improve
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report
The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III
Cost-Effectiveness of Using Clinical Risk Factors with and without DXA for Osteoporosis Screening in Postmenopausal Women
The Economic Value of Innovative Treatments over the Product Life Cycle: The Case of Targeted Trastuzumab Therapy for Breast Cancer
Costs and Health Utilities Associated with Extremely Preterm Birth: Evidence from the EPICure Study
Comparative Analysis of Length of Stay, Total Costs, and Treatment Success between Intravenous Moxifloxacin 400 mg and Levofloxacin 750 mg among Hospitalized Patients with Community-Acquired Pneumonia
Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life Questionnaire
Mapping the Cancer-Specific EORTC QLQ-C30 to the Preference-Based EQ-5D, SF-6D, and 15D Instruments
A Concept Taxonomy and an Instrument Hierarchy: Tools for Establishing and Evaluating the Conceptual Framework of a Patient-Reported Outcome (PRO) Instrument as Applied to Product Labeling Claims
Psychometric Evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)—A Measure of Symptom Distress
Psychometric Properties of a German Version of the “Satisfaction with Information about Medicines Scale” (SIMS-D)
Patient Experiences of Continuity of Cancer Care: Development of a New Medical Care Questionnaire (MCQ) for Oncology Outpatients
South Korean Time Trade-Off Values for EQ-5D Health States: Modeling with Observed Values for 101 Health States
International Comparisons in Valuing EQ-5D Health States: A Review and Analysis
Too Much Ado about Instrumental Variable Approach: Is the Cure Worse than the Disease?
Probabilistic Sensitivity Analysis: Be a Bayesian
REVIEWER ACKNOWLEDGMENT